在第16周,平均约75%接受Zasocitinib (中译:泽索昔替尼*,下称泽索昔替尼)治疗的头皮银屑病患者,以及约70%接受泽索昔替尼治疗的掌跖部位银屑病患者达到皮损清除或几乎清除。 与安慰剂相比,泽索昔替尼在甲银屑病严重程度指数(NAPSI)方面显示出具有统计学意义的改善。 结果进一步支持泽索昔替尼有望成为中度至重度斑块状银屑病患者的便捷的每日一次口服治疗选择,帮助患者实现快速、持久且有意义...
Source Link在第16周,平均约75%接受Zasocitinib (中译:泽索昔替尼*,下称泽索昔替尼)治疗的头皮银屑病患者,以及约70%接受泽索昔替尼治疗的掌跖部位银屑病患者达到皮损清除或几乎清除。 与安慰剂相比,泽索昔替尼在甲银屑病严重程度指数(NAPSI)方面显示出具有统计学意义的改善。 结果进一步支持泽索昔替尼有望成为中度至重度斑块状银屑病患者的便捷的每日一次口服治疗选择,帮助患者实现快速、持久且有意义...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.